Be Careful In Canada

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news. We post this and all of the newsletters on our website here.


This was a big week for the Canadian cannabis industry, with the the Legislative Review of the Cannabis Act published yesterday afternoon. The Expert Panel, a group of five that wrote the report, was appointed by the Minister of Health and the Minister of Mental Health and Addictions. The Cannabis Act legalized adult-use in Canada in late 2018, and this was the first official review.

Chapter 2, which begins on the tenth page, lists 54 recommendations, but this falls short of making some very necessary changes to the regulation of the world’s first legalized cannabis nationwide in a large developed country. We have pointed out some of the flaws in the market, including the distribution through the provinces for most of the country, the limits on THC per package in edibles at just 10mg, and the high level of taxation.

The market is very mature now and is showing signs of its age. This morning, the January sales, released by Statistics Canada, showed the slowest annual growth to date. Total sales of C$400.1 million grew just 1% from a year ago:

The stocks in the sector have popped recently. The 5 stocks that are in the NCV Global Cannabis Stock Index and that trade over $1 are still down year-to-date for the most part:

The one that is up a lot is Organigram, which we have written about here in the past very bullishly. I exited it in my model portfolio at 420 Investor yesterday after the rally, which leaves it slightly above tangible book value. I have also mentioned Village Farms here, and I have greatly reduced my position on this stock that trades at just 50% of its tangible book value. It’s not in the index and is up -24.8% year-to-date.

We are still worried about Canopy Growth’s prospects, and we find Tilray to be quite expensive. The big rallies in the names that we have liked have left them not as promising right now. Today’s news about weakening demand in Canada adds to reasons to be cautious on Canadian cannabis stocks.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most important content from this week:

Exclusive Articles

Canadian Cannabis Sales Slump

Cannabis Company Q4 Financials Were Not Exciting

Capital Raising

Cannabist Closes Convertible Note Offering

Ispire Technology Sells 2.05 Million Shares at $6.00

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer the Canadian Cannabis LP Index, the American Cannabis Operator Index and the Ancillary Cannabis Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.



Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter